Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지

Effects of Metformin and Rosiglitazone in Overweight or Obese Women with Polycystic Ovarian Syndrome

과체중 및 비만 다낭성 난소 증후군 환자에서의 Metformin과 Rosiglitazone의 효용성

  • Bai, Kwang Bum (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
  • 배광범 (서울대학교 의과대학 산부인과학교실)
  • Published : 2005.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The purpose of this study was to evaluate and compare the effects of metformin and rosiglitazone in overweight or obese women with polycystic ovarian syndrome. Methods: Twenty Six overweight or obese patients with polycystic ovarian syndrome were randomly treated with either metformin (500 mg three times daily, n=13) or rosiglitazone (4 mg once daily, n=13) for 6 months. Hormonal studies were performed before and after treatment. Insulin resistances were calculated by computerized HOMA 2 Calculator v2.2. Results: Testosterone decreased while SHBG increased after 6 months treatment in both metformin and rosiglitazone treatment groups. Fasting glucose decreased after metformin or rosiglitazone treatment. HOMA insulin resistance improved after treatment with either drug. There was no differences in hormonal changes and insulin resistance between 2 treatment groups. Conclusions: This study shows that metformin and rosiglitazone are effective in improving insulin sensitivity and ameliorating hyperandrogenism in overweight/obese polycystic ovarian syndrome women.

Keywords

Acknowledgement

Supported by : 서울대보라매병원

References

  1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61 https://doi.org/10.1056/NEJM199509283331307
  2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-82 https://doi.org/10.1210/jc.83.9.3078
  3. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovarian syndrome. Diabetes 1992; 41: 1257-66 https://doi.org/10.2337/diabetes.41.10.1257
  4. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinemia in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113-6 https://doi.org/10.1210/jcem-50-1-113
  5. Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989; 68: 1027-32 https://doi.org/10.1210/jcem-68-6-1027
  6. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackared WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-9 https://doi.org/10.1210/jcem-72-1-83
  7. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83: 2001-5 https://doi.org/10.1210/jc.83.6.2001
  8. Azziz R. Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 2003; 80: 252-4
  9. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001; 286: 2421-6 https://doi.org/10.1001/jama.286.19.2421
  10. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-12 https://doi.org/10.1210/er.2003-0004
  11. Lord JM, Flight IH, Norman RJ. Insulin-sensitizing drugs (metforrnin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; 3: CD003053
  12. Nagi DK, Yudkin JS. Effects of metforrnin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993; 16: 621-9 https://doi.org/10.2337/diacare.16.4.621
  13. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metforrnin action in obese and lean noninsulin dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-301 https://doi.org/10.1210/jcem-73-6-1294
  14. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovarian syndrome. J Clin Endocrinol Metab 1996; 81: 3299-306 https://doi.org/10.1210/jc.81.9.3299
  15. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stmulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin endocrinol Metab 1986; 62: 904-10 https://doi.org/10.1210/jcem-62-5-904
  16. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17$alpha$ activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-623. https://doi.org/10.1056/NEJM199608293350902
  17. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone binding globulin production in human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67: 460-6 https://doi.org/10.1210/jcem-67-3-460
  18. Costello MF, Eden JA. A systematic review of the reproductive system effects of metforrnin in pateints with polycystic ovary syndrome. Fetril Steril 2003; 79: 1-13 https://doi.org/10.1016/S0015-0282(02)04554-5
  19. Nestler JE, Jakubowica DJ, Evans WS, Pasquali R. Effects of metfonnin on spontaneousand clomipheneinduced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876-80 https://doi.org/10.1056/NEJM199806253382603
  20. Fleming R, Hopkinson Z, Wallace R. Ovarian function and metabolic factors in women with oligomenorrhea treated with metfonnin in a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 569-74 https://doi.org/10.1210/jc.87.2.569
  21. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metfonnin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524-30 https://doi.org/10.1210/jc.82.2.524
  22. Azzia R, Ehrmann D, Legro R, Whitcomb RW, Hanley R, Gmerek Fereshetian A, O'keefe M, Ghazzi MN, PCOSffroglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-32 https://doi.org/10.1210/jc.86.4.1626
  23. Baillargeon JP, Iuomo MJ, Nestler JE. Comparison of metforrnin and thiazolidinediones in the management of plolycystic ovary syndrome. Curr Opin Endocrinol Diabetes 2002; 9: 303-11 https://doi.org/10.1097/00060793-200208000-00003
  24. Harborne, L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metfonnin in polycystic ovary syndrome. Lancet 2003; 361: 1894-901 https://doi.org/10.1016/S0140-6736(03)13493-9
  25. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metforrnin therapy in polycystic ovary syndrome redeces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-54 https://doi.org/10.1016/0026-0495(94)90209-7
  26. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G, et al. Responses of serum androgen and insulin resistance to metforrnin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1360-5 https://doi.org/10.1210/jc.2004-1965
  27. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115(Suppl 8A): 42S-48S https://doi.org/10.1016/j.amjmed.2003.09.005
  28. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067-71 https://doi.org/10.2337/diacare.23.8.1067
  29. Kelly IE, Han TS, Walsh K, Lean MEJ. Effects of a thiazolidinedione compound on body fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-93 https://doi.org/10.2337/diacare.22.2.288
  30. Wallace T, Levy J, Matthews D. Use and abuse of HOMA modeling. Diabetic Care 2004; 27: 1487 -1495 https://doi.org/10.2337/diacare.27.6.1487